In recent years, studies have shown that brain natriuretic peptide (BNP), N-terminal pro- brain natriuretic peptide (NT-proBNP), asymmetric dimethylarginine (ADMA), and vascular endothelial growth factor (VEGF) may be potential diagnostic biomarkers for PAH-CHD, but the specificity of these biomarkers is still controversial [6, 7]. The gene discussed is VEGFA; the disease is pulmonary arterial hypertension.